Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Eric L Simpson; Adelaide A Hebert; John Browning; Rocco T Serrao; Howard Sofen; Philip M Brown; Stephen C Piscitelli; David S Rubenstein; Anna M Tallman

doi:10.1007/s13555-024-01318-6

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Dermatol Ther (Heidelb). 2025 Jan 7. doi: 10.1007/s13555-024-01318-6. Online ahead of print.

Authors

Eric L Simpson¹, Adelaide A Hebert², John Browning³, Rocco T Serrao⁴, Howard Sofen⁵, Philip M Brown⁶, Stephen C Piscitelli⁶, David S Rubenstein⁶, Anna M Tallman⁶

Affiliations

¹ Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR, 97239-3098, USA. [email protected].
² UTHealth McGovern School of Medicine and Children's Memorial Hermann Hospital, Houston, TX, USA.
³ UT Health San Antonio, San Antonio, TX, USA.
⁴ Dermatologists of Southwest Ohio, Mason, OH, USA.
⁵ David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁶ Dermavant Sciences, Inc., Morrisville, NC, USA.

PMID: 39777610
DOI: 10.1007/s13555-024-01318-6

Abstract

Introduction: Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in patients down to age 2 years with AD. Here, we evaluate patient-reported outcomes (PROs), including family impact, with tapinarof in ADORING 1 and 2.

Methods: In ADORING 1 and 2, 813 patients were randomized to tapinarof or vehicle QD for 8 weeks. PROs were assessed using the Dermatology Life Quality Index (DLQI), Children's Dermatology Life Quality Index (CDLQI), Infants' Dermatitis Quality of Life Index (IDQOL), Dermatitis Family Impact Questionnaire (DFI), and Patient Oriented Eczema Measure (POEM).

Results: Mean baseline DLQI, CDLQI, IDQOL, and DFI scores indicated that the impact on families and patients' quality of life (QoL) of AD was moderate to very large. Mean POEM scores indicated moderate to severe AD symptoms at baseline. Tapinarof improved QoL versus vehicle across all endpoints at week 8: DLQI, - 6.2 vs - 3.5 (P = 0.0031) and - 5.5 vs - 3.5 (P = 0.0028); DFI, - 5.6 vs - 2.9 (P < 0.0001) and - 5.6 vs - 3.8 (P = 0.0037), in ADORING 1 and 2, respectively. Similar improvements in CDLQI and IDQOL were reported with tapinarof versus vehicle. Tapinarof also significantly improved CDLQI, DFI, and POEM sleep subdomain scores versus vehicle. POEM scores also improved with tapinarof versus vehicle: ≥ 12 years, - 9.4 vs - 5.3 and - 10.6 vs - 3.6 (both P < 0.0001); < 12 years, - 11.4 vs - 5.7 (P < 0.0001), and - 10.8 vs - 7.3 (P = 0.0005).

Conclusions: Tapinarof significantly improved QoL across PROs, including sleep and family impact, regardless of age, from week 1 (the earliest evaluation) through week 8. Tapinarof is a once-daily, non-steroidal cream that rapidly improves AD symptoms, sleep, and QoL in patients down to age 2 years with AD.

Trial registration: Clinical Trials.gov identifier: NCT05014568; NCT05032859.

Keywords: Atopic dermatitis; Family impact; Patient-reported outcomes; Quality of life; Sleep improvement; Tapinarof cream 1% once daily; Topical aryl hydrocarbon receptor agonist.

Associated data

ClinicalTrials.gov/NCT05032859
ClinicalTrials.gov/NCT05014568